Verimatrix Receives 2025 Intellyx Digital Innovator Award
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it won the 2025 Intellyx Digital Innovator Award. Recognizing the innovation within Verimatrix Extended Threat Defense (XTD), the prestigious accolade underscores the solution's unique arsenal of defensive techniques including code obfuscation, anti-tamper technology, and environmental checks that shield mobile apps, detect threats, and respond to them effectively.
Verimatrix XTD continually arms some of the world's top mobile app brands with the latest security technologies to consistently protect their app-centric business. It's the go-to security solution for organizations looking to proactively protect vital mobile apps from today's wide range of threats such as supply chain attacks, screen overlays, application repackaging, illicit modification or tampering, man-in-the-device attacks, and more. XTD's advanced obfuscation techniques as well as its threat detection and response capabilities using AI/ML, put XTD into an enterprise class like few others.
'Receiving the Intellyx Digital Innovator Award is a true honor — and it underscores how Verimatrix XTD is helping redefine what's possible in mobile app security,' said Jon Samsel, head of cybersecurity business and global marketing at Verimatrix. 'It's a testament to our team's relentless commitment to innovation and our drive to stay ahead of an ever-evolving threat landscape.'
'We were interested in Verimatrix because of the unique app delivery pipeline perspective they bring to the mobile threat detection and response space,' said Jason English, Director and Principal Analyst, Intellyx. 'To truly embrace zero-trust security practices for mobile apps, it is wise to assume that every listing in an app store is constantly under surveillance by bots and code inspectors, and that every install of the app could be going onto a rooted device under the control of a hacker.'
An Intellyx white paper titled 'Understanding the Four Quadrants of Mobile App Security' is available to download at: https://intellyx.com/2025/04/29/whitepaper-understanding-the-four-quadrants-of-mobile-app-security/
For more details on the award and to see other winning vendors in this group, visit www.intellyx.com or the 2025 Intellyx Digital Innovator awards page.
About Intellyx
Intellyx is the first and only industry analysis, advisory and training firm focused on customer-driven, technology-empowered digital transformation for the enterprise. Covering every angle of enterprise IT from mainframes to cloud, process automation to artificial intelligence, our broad focus across technologies allows business executives and IT professionals to connect the dots on disruptive trends. Read and learn more at www.intellyx.com or follow them on LinkedIn.
About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
05-08-2025
- Business Upturn
E-Invoicing: Quadient Reaches Key Milestone as Serensia Successfully Passes French Tax Authority Testing
E-Invoicing: Quadient Reaches Key Milestone as Serensia Successfully Passes French Tax Authority Testing Quadient (Euronext Paris: QDT), a global intelligent automation platform enabling secure and professional business connections, announced today that Serensia, its recent acquisition in the digital segment, has successfully completed interoperability testing in live conditions as part of France's phased rollout of mandatory e-invoicing. Serensia, a certified French e-invoicing platform connected to the Peppol network, was selected by the French Public Finance Department, along with two other platforms, formerly designated as Partner Dematerialization Platforms (PDP) and now referred to as Certified Platforms, to participate in the first round of interoperability testing. Conducted under real-world conditions, the tests validated the public directory's interaction with other platforms and the government's data hub. Beyond demonstrating technical capabilities, the initiative reflects a broader commitment to strengthening collaboration between private-sector players and public authorities. The results confirm Serensia's robustness, reliability and compliance, marking a major step forward in Quadient's readiness and reaffirming its ability to support businesses in meeting the requirements of the e-invoicing reform. 'The French Public Finance Department's selection of Serensia for the initial round of real-world testing speaks to the strength of the solution,' said Geoffrey Godet, CEO of Quadient. 'Its successful compliance testing validates the strategic choices we've made, particularly the acquisition of Serensia, which now positions Quadient at the forefront of the reform's implementation across all French companies. Our message to businesses is clear: transitioning to e-invoicing requires preparation, and Quadient is more ready than ever to support them with a proven, reliable and compliant solution.' As of July 1, the central directory listing all VAT-registered businesses has gone live. Quadient is already able to register clients who have granted it a mandate, in accordance with the government-defined process. Through its subsidiary Serensia or its own certified platform, the company is preparing for its final registration, expected in fall 2025. This will enable it to fully support large enterprises, mid-sized companies, SMEs and accounting firms in the digital transition mandated by the reform. To learn more about Quadient's invoicing and payment solutions, visit: About Quadient® Quadient is a global automation platform powering secure and sustainable business connections through digital and physical channels. Quadient supports businesses of all sizes in their digital transformation and growth journey, unlocking operational efficiency and creating meaningful customer experiences. Listed in compartment B of Euronext Paris (QDT) and part of the CAC® Mid & Small and EnterNext® Tech 40 indices, Quadient shares are eligible for PEA-PME investing. For more information about Quadient, visit Media Contacts Joe Scolaro, QuadientGlobal Press Relations Manager+1 203-301-3673 [email protected]
Business Wire
04-08-2025
- Business Wire
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025
MARSEILLE, France--(BUSINESS WIRE)--Regulatory news: Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as of August 1, 2025: (1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017. (2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Business Wire
29-07-2025
- Business Wire
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') today announced that the company's CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. BTIG, a global financial services firm specializing in investment banking, institutional trading, research and related brokerage services, recently initiated analyst coverage of Innate Pharma. The Fireside chat will be held on Wednesday July 30 at 2pm EST, with 1x1 meetings hosted the same day. About BTIG BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 20 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
